News

Brussels, 22/04/2025 – The Erasmus Hospital (H.U.B) is pleased to announce a major transformation of its Emergency Department. The result of an in-depth reflection on modern emergency medicine and the continuous improvement of care, this remodelling marks a crucial new stage in the development of emergency treatment in Belgium. One inspired by the “Moving Forward” concept as employed by the most modern emergency services.

Brussels, 28 February 2025 – In Belgium, one in twenty people is affected by a rare disease. But beyond the often complex diagnosis, these
patients face a "double burden": the disease itself and the numerous systemic obstacles to accessing care. On the occasion of Rare Disease
Day, an open letter signed by Franck Devaux, Ethicist and President of the Ethics Committee at HUDERF, Coordinator of the Rare Diseases
Function at H.U.B, and Professor Béatrice Gulbis, Director of the Rare Diseases Function at H.U.B and Co-Coordinator of EuroBloodNet, the
European Reference Network for rare hematological diseases, calls for collective awareness and concrete actions to ensure fairer and more
inclusive care.

Brussels, 21 January 2025 – The Department of Interventional Radiology at the Brussels University Hospital (H.U.B) is now proposing a promising and minimally invasive new treatment for adhesive capsulitis. Clinical results obtained to date confirm its effectiveness where other treatments have failed, even in the most advanced cases.

In November, “Bordet is pulling out all the stops”. In launching this campaign, the H.U.B care teams are seeking to increase awareness and encourage discussion of male cancers. With the fear of losing their masculinity and a sense of shame or embarrassment in talking about it, men rarely dare open up about their physical or mental health. Yet they are also at risk of being affected by cancer at some point in their lives.  Removing taboos and opening up about the disease are nonetheless essential when you consider that the earlier a cancer is detected the greater the chances of remission. At the Jules Bordet Institute, which is a part of the Brussels University Hospital (H.U.B), each patient receives global and personalised care adapted to their pathology, from detection through to treatment and post-cancer monitoring. The expertise of the multidisciplinary teams combined with the state-of-the-art technology provide the best guarantees of maintaining the patient’s quality of life.

A EUR 16 million Initiative to Establish Strategic EU Autonomy in Alpha Therapies for Cancer 

The Brussels University Hospital (H.U.B.) proudly stands at the forefront of a revolutionary advancement in the treatment of sickle cell disease: gene therapy. This breakthrough marks a new era in the management of this devastating genetic disorder, offering unprecedented hope to patients and their families.